Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
11.58
-0.65 (-5.31%)
At close: Jul 25, 2025, 4:00 PM
12.20
+0.62 (5.35%)
After-hours: Jul 25, 2025, 7:22 PM EDT
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $98.15M in the quarter ending March 31, 2025, with 258.77% growth. This brings the company's revenue in the last twelve months to $199.73M, up 475.53% year-over-year. In the year 2024, Atara Biotherapeutics had annual revenue of $128.94M with 1,404.02% growth.
Revenue (ttm)
$199.73M
Revenue Growth
+475.53%
P/S Ratio
0.51
Revenue / Employee
$1,305,438
Employees
153
Market Cap
78.69M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
Dec 31, 2021 | 20.34M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ATRA News
- 2 days ago - Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 2 days ago - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire
- 11 days ago - Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PRNewsWire
- 12 days ago - Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®) - Business Wire
- 2 months ago - Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - Business Wire
- 2 months ago - Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress - Business Wire
- 2 months ago - Atara Biotherapeutics Announces Pricing of $16 Million Offering - Business Wire
- 2 months ago - Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) - Business Wire